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Sapovirus (SaV) protease catalyzes cleavage of the peptide bonds at six sites of a viral
polyprotein for the viral replication and maturation. However, the mechanisms by which
the protease recognizes the distinct sequences of the six cleavage sites remain poorly
understood. Here we examined this issue by computational and experimental approaches.
A structural modeling and docking study disclosed two small clefts on the SaV protease
cavity that allow the stable and functional binding of substrates to the catalytic cavity
via aromatic stacking and electrostatic interactions. An information entropy study and a
site-directed mutagenesis study consistently suggested variability of the two clefts under
functional constraints. Using this information, we identified three chemical compounds that
had structural and spatial features resembling those of the substrate amino acid residues
bound to the two clefts and that exhibited an inhibitory effect on SaV protease in vitro.These
results suggest that the two clefts provide structural base points to realize the functional
binding of various substrates.
Keywords: sapovirus protease, substrate recognition, P1 and P4 amino acid residues, 3-D models, amino acid
diversity, mutagenesis, 3-D pharmacophore, inhibitor screening
INTRODUCTION
Sapovirus (SaV) is a non-enveloped RNA virus that belongs to
the family Caliciviridae and causes gastroenteritis in humans and
swine (Chiba et al., 1979, 2000; Guo et al., 1999; Hansman et al.,
2007). The SaV genome is a single-stranded RNA that encodes
two or three open reading frames (ORFs; Liu et al., 1995; Noel
et al., 1997; Numata et al., 1997; Guo et al., 1999; Robinson et al.,
2002). The ORF1 encodes six non-structural proteins (NS1, NS2,
NS3, NS4, NS5, and NS6-7) and a structural protein, the capsid
protein (VP1; Oka et al., 2006, 2009). The NS6-7 protein contains
the chymotrypsin-like protease domain (the 3C-like protease; Oka
et al., 2005a,b, 2007; Robel et al., 2008) and the RNA-dependent
RNA polymerase domain (the 3-D-like polymerase; Fullerton
et al., 2007; Bull et al., 2011). The ORF1 precursor protein is post-
translationally cleaved at six sites by the 3C-like protease (Oka
et al., 2005b, 2006).
The SaV 3C-like protease domain comprises 146 amino acid
residues (Oka et al., 2007). This enzyme cleaves the peptide bonds
of specific dipeptides, such as the glutamic acid/glycine (E/G), glu-
tamine/glycine (Q/G), and glutamic acid/alanine (E/A; Oka et al.,
2006). However, these dipeptide motifs exist in the non-cleaved
sites of the ORF1 polyprotein, indicating that additional amino
acid residues are required for the specific recognition of sub-
strates (Oka et al., 2006). In this regard, calicivirus proteases
have a large cavity that can accommodate substrate peptides with
several amino acid in lengths (Nakamura et al., 2005; Zeitler
et al., 2006; Oka et al., 2007). It is conceivable that these sub-
strate amino acid residues around the cleavage sites, termed the
P4, P3, P2, P1, P1′, P2′, P3′, and P4′ sites, are all involved to
some extent, either directly or indirectly, in the recognition and
cleavage by protease. However, there must be a division of roles:
previous studies on the calicivirus proteases consistently suggest
more extensive involvement of the substrate amino acid residues
upstream of the peptide bond of the cleavage sites in the cleav-
age by proteases (Wirblich et al., 1995; Sosnovtsev et al., 1998;
Hardy et al., 2002; Belliot et al., 2003; Scheffler et al., 2007; Robel
et al., 2008). In the case of SaV, the substrate P1 and P4 amino
acid residues in particular are physicochemically more conserved
among different SaV strains (Oka et al., 2009) and more sensi-
tive to the substitutions (Robel et al., 2008; Oka et al., 2009).
Therefore, these amino acid residues may provide the specific con-
tact sites with SaV protease. However, due to the lack of structural
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information on SaV protease and its substrates, such interaction
remains unclear.
Recent advances in the hardware and software for biomolecular
simulation and bioinformatics have rapidly improved the preci-
sion and performance of these techniques. We have applied some
of these techniques, in combination with experimental methods,
to understand the structural and evolutionary basis of the viro-
logical phenomena (Oka et al., 2007, 2009; Motomura et al., 2008,
2010; Naganawa et al., 2008; Shirakawa et al., 2008;Yokoyama et al.,
2010, 2012; Ode et al., 2011; Sakuragi et al., 2012). In this study, by
combining methods of homology modeling, the automated ligand
docking, Shannon entropy analysis, site-directed mutagenesis, and
in silico screening of SaV inhibitors, we studied the structural basis
for the substrate recognition by SaV protease.
MATERIALS AND METHODS
STRUCTURAL MODELING OF SaV PROTEASE DOCKED TO THE
SUBSTRATE OCTAPEPTIDES
We first constructed a ligand-free protease domain model of the
SaV Mc10 strain (Oka et al., 2005b; GenBank accession number:
AY237420) by the homology modeling technique (Sanchez et al.,
2000; Baker and Sali, 2001) as described previously (Oka et al.,
2007). The modeling was performed using tools available in the
Molecular Operating Environment (MOE; Chemical Computing
Group, Inc., Montreal, QC, Canada). As the modeling template,
we used the high-resolution crystal structure of norovirus 3C-
like protease at a resolution of 1.50 Å [Protein Data Bank (PDB)
code: 2FYQ; Zeitler et al., 2006] because, like SaV, the norovirus
belongs to the family Caliciviridae, and thus the protease sequence
shows a higher identity to the SaV protease sequences (about 25%
identity) than to the other available 3C-like protease sequences
of viruses. We applied the multiple sequence alignment approach
(Baker and Sali, 2001) using the reported 3C-like proteases to
minimize misalignments of the target and template sequences, as
described previously (Oka et al., 2007; Shirakawa et al., 2008). The
sequences used for the alignment included those of the rhinovirus
3C-like protease (PDB code: 1CQQ; Matthews et al., 1999), the
poliovirus 3C-like protease (PDB code: 1L1N; Mosimann et al.,
1997), and the hepatitis A virus 3C-like protease (PDB code: 1QA7;
Bergmann et al., 1999). The alignment was done with the align-
ment tool MOE-Align, and homology modeling was done with the
tool MOE-Homology in MOE. We optimized the 3-D model ther-
modynamically via energy minimization using the MOE and an
AMBER99 force field (Ponder and Case, 2003). We further refined
the physically unacceptable local structure of the models based
on a Ramachandran plot evaluation using MOE. The 3-D models
of the six octapeptides corresponding to the six cleavage sites of
the ORF1 precursor protein of the SaV Mc10 strain (NS1/NS2,
NS2/NS3, NS3/NS4, NS4/NS5, NS5/NS6-7, and NS6-7/VP1) were
constructed using the Molecular Builder module in MOE. Subse-
quently, the thermodynamically and physically optimized protease
models were used to construct protease-substrate complex mod-
els. Individual octapeptide models were docked with the optimized
SaV protease domain model described above, using the automated
ligand docking program ASEDock2005 (Goto et al., 2008) oper-
ated in MOE as described previously (Yokoyama et al., 2010).
Default setting in ASEDock2005 was applied for the search of
the candidate docking structures, and the structures with the best
docking score expressed by the arbitrary docking energy (U dock)
in ASEDock2005 (Kataoka and Goto, 2008) were selected for the
analysis of the protease-substrate interaction sites.
ANALYSIS OF AMINO ACID DIVERSITY WITH INFORMATION ENTROPY
The amino acid diversity at individual sites of the SaV pro-
tease domain was analyzed with Shannon entropy scores as
described previously (Sander and Schneider, 1991; Mirny and
Shakhnovich, 1999; Oka et al., 2009). The amino acid sequences
of the protease domain of various human SaV strains from
different geographic regions in the world were obtained from
GenBank (the number of sequences is 19; accession numbers:
X86560, AY694184, AY237422, AY237423, AY646853, AY646854,
AJ249939, AY237420, AY237419, AY646855, AY603425, AJ786349,
DQ058829, DQ125333, AY646856, DQ125334, DQ366344,
DQ366345, DQ366346). The amino acid diversity within the
SaV protease population was calculated using Shannon’s formula
(Shannon, 1948):
H (i) = −
∑
xi
p (xi) log2p (xi) (xi = G, A, I , V , . . . . . .) ,
where H(i), p(xi), and i indicate the amino acid entropy (H ) score
of a given position, the probability of occurrence of a given amino
acid at the position, and the number of the position, respectively.
An H score of zero indicates absolute conservation, whereas 4.4
bits indicates complete randomness. The H scores were displayed
on the 3-D structure of the SaV protease model constructed above.
We also calculated the Shannon entropy by considering the
physicochemical properties of amino acid residues, i.e., the chem-
ical properties and size of side chains as described previously (Oka
et al., 2009). For analysis of the diversity in the chemical properties,
the amino acid residues were classified into seven groups: acidic
(D,E), basic (R,K,H), neutral hydrophilic (S, T, N, Q), aliphatic
(G, A, V, I, L, M), aromatic (F, Y, W), thio-containing (C), and
imine (P). For analysis of the diversity in the size of side chains,
the amino acid residues were classified into four groups: small (G,
A, C, S), medium-small (T, V, N, D, I, L, P, M), medium-large (Q,
E, R, K), and large (H, F, Y, W). The H scores were plotted on the
3-D structure of the SaV protease model.
SITE-DIRECTED MUTAGENESIS OF THE SaV PROTEASE DOMAIN
The detailed strategy of the mutagenesis for the SaV pro-
tease domain has been described previously (Oka et al., 2005b,
2006). Briefly, we used the full-length cDNA clone of the
genome of the SaV strain Mc10 (pUC19/SaV Mc10 full-
length; GenBank accession number: AY237420) as a start-
ing material for the mutagenesis. We constructed nine SaV
Mc10 full-length mutant cDNA clones. Site-directed mutagene-
sis was performed using a GeneTailor Site-Directed Mutagene-
sis System (Invitrogen). The oligonucleotides used for the site-
directed mutagenesis were as follows (the codons correspond-
ing to changed amino acid(s) are indicated in lowercase): for
T1085A, 5′-GTGGTTGTCACAGTTgcaCACGTGGCCTCTGCG-
3′; for Y1156A, 5′-ATCACGGTCCAGGGGgctCACCTGCGCATC
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ATA-3′; for K1167A, 5′-ATGGATACCCAACAgcgCGTGGGGACT
GTGGCAC-3′; for R1168A,5′-GATACCCAACAAAGgctGGGGAC
TGTGGCACAC-3′; for K1167E, 5′-ATGGATACCCAACAgagCGT
GGGGACTGTGGCAC-3′; for R1168E, 5′-ATGGATACCCAACAA
AGgagGGGGACTGTGGCACAC-3′; for K1167AR1168A, 5′-
ATGGATACCCAACAgcggcgGGGGACTGTGGCAC-3′; and for
K1167ER1168E, 5′-ATGGATACCCAACAgaggagGGGGACTGTG
GCAC-3′. The T1085AY1156A mutant was generated with the
above Y1156A primer using methylated DNA of the T1085A as
the template. All the mutant clones constructed were subjected to
the sequencing of the entire genomic cDNA region to verify the
absence of unnecessary mutations leading to amino acid changes.
IN VITRO TRANSCRIPTION-TRANSLATION ASSAY
In vitro transcription-translation with a rabbit reticulocyte
system was performed using the TNT T7 Quick for PCR
DNA kit (Promega, Madison, WI, USA) as described previ-
ously (Oka et al., 2005b). Briefly, a template for the in vitro
transcription-translation, containing the entire ORF1, was pre-
pared by PCR amplification using the full-length cDNA clone.
The primers used for the amplification were as follows. The for-
ward primer containing a T7 promoter sequence (underlined)
and a translation initiation codon (bold) was 5′-GGATCCTAA
TACGACTCACTATAGGGAACAGCCACCATG gcttccaagccattcta
cccaatagag-3′; and the antisense primer containing a stop codon
(bold) was 5′-T30TTA-ttctaagaacctaacggcccgg. The PCR product
(3µl) was mixed with 20µl of TNT T7 PCR Quick Master Mix
(Promega) and 2µl of Redivue Pro-mix L- [35S] in vitro cell-
labeling mix (GE Healthcare Biosciences, Piscataway, NJ, USA).
The mixture was incubated at 30˚C for 3 or 16 h and subjected to
SDS-polyacrylamide gel electrophoresis (SDS-PAGE). The trans-
lation products separated by electrophoresis were blotted onto a
PVDF membrane (Immobilon-P; Millipore, Bedford, MA, USA)
using a semi-dry electroblotting apparatus (ATTO; Tokyo). The
radiolabeled proteins were detected by a BAS 2500 Bioimage
Analyzer (Fuji Film, Tokyo).
IMMUNOPRECIPITATION
For the detection of NS1 (p11) and NS5 (VPg), which were
undetectable with the above assay system, we performed immuno-
precipitation before the SDS-PAGE as described previously (Oka
et al., 2005b, 2006, 2009). Briefly, 10µl of the in vitro transcription-
translation reaction mixture was diluted with 80µl of RIPA lysis
buffer containing 50 mM Tris, pH 7.4, 150 mM NaCl, 0.25%
deoxycholic acid, 1% NP40, and 1 mM EDTA (Upstate, Lake
Placid, NY, USA) and incubated with 5µg of anti-A (anti-NS1)
or ant-D (anti-NS5) antibodies raised against E. coli-expressed
recombinant proteins (aa 1–231 for NS1 and aa 941–1055 for
NS5; Oka et al., 2005b). After incubation for 1 h on ice, 25µl
of a suspension of Protein A Magnetic Beads (New England
Biolabs) and 900µl of RIPA buffer were added. The mixture
was gently rotated at 4˚C for 1 h and then washed three times
with 1 ml of RIPA lysis buffer. The immunoprecipitated pro-
teins were resuspended in 20µl of SDS-PAGE sample buffer
and heated at 95˚C for 5 min prior to analysis with 5 to 20%
Tris-Gly polyacrylamide gel. The proteins were blotted onto an
Immobilon-P polyvinylidene difluoride membrane (Millipore).
Immunoprecipitated radioactive proteins were detected with a
Bioimage Analyzer BAS 2500 (Fuji Film).
THE CHEMICAL COMPOUND LIBRARY
Chemical compounds (139,369 compounds, molecular weights
42–2986) were obtained from the Open Innovation Center for
Drug Discovery (The University of Tokyo, Tokyo, Japan). The
compound library database of this center provides information
on the molecular formula, molecular weight, hydrogen-bond
donor-acceptor numbers, topological polar surface area (TPSA),
and other physicochemical parameters of the compounds for
pharmacophore-based in silico drug screening.
PHARMACOPHORE-BASED IN SILICO SCREENING
Pharmacophore-based in silico screening was done using tools
available in the MOE. We created a pharmacophore query with
a substrate feature using the Pharmacophore Query Editor tool
in MOE. Pharmacophore-based in silico screening was done by
the Pharmacophore Search module in the MOE using the created
query.
DRUG SUSCEPTIBILITY ASSAY
The susceptibility of SaV protease to the synthetic small chem-
ical compound was determined by means of an in vitro trans
cleavage assay as follows. A radiolabeled full-length Mc10 ORF1
polyprotein containing a defective protease (Promut; Oka et al.,
2005b) or a non-radiolabeled partial Mc10 ORF1 polyprotein
(NS6-7-VP1) containing a functional protease (Prowt; Oka et al.,
2006) was separately expressed using the in vitro transcrip-
tion/translation system (Oka et al., 2011). The PCR primer pairs
used for the preparation of DNA template for the expression
of the NS6-7-VP1 were as follows. The forward primer was 5′-
GGATCCTAATACGACTCACTATAGGGAACAGCCACCATGgctc
ccacaccaattgttac-3′, including the T7 promoter sequence (under-
lined) and a start codon (bold); and the antisense primer was
5′-T30TTA-ttctaagaacctaacggcccgg, including a stop codon (bold).
Twenty microliter of the non-radiolabeled products containing
Prowt was mixed with 1µl of 2 mM inhibitor candidate in DMSO
and incubated for 10 min at room temperature. Then 10µl of the
radiolabeled full-length ORF1 polyprotein (Promut) was added to
the Prowt-inhibitor mixture and incubated at 30˚C for 20 h, and
subjected to the SDS-PAGE analysis as described above. To quan-
titate the proteolytic activity of the SaV protease, we measured the
intensity of the band corresponding to the NS4-NS5 intermediate
processing product with Typhoon 7500 (GE Healthcare), due to
the lack of overlapping non-specific products of the in vitro trans-
lation around the NS4-NS5. The chemical compound concentra-
tions resulting in a 50% reduction of the NS4-NS5 intermediate
protein production of the drug-free control were determined on
the basis of the dose-response curve and defined as the IC50 values
of the SaV proteolysis activity.
STRUCTURAL MODELING OF SaV PROTEASE DOCKED TO CHEMICAL
COMPOUNDS
Structural models of the chemical compounds were constructed
using the Molecular Builder tool in MOE. Individual compounds
were docked with the SaV protease domain model using the auto-
mated ligand docking program ASEDock2005 (Goto et al., 2008)
operated in MOE as described above.
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RESULTS
STRUCTURAL MODELING OF SaV PROTEASES DOCKED TO THE
SUBSTRATE OCTAPEPTIDES
To obtain structural insights into the protease-substrate interac-
tions at the atomic level, we constructed a 3-D model of the intact
protease domain of the SaV Mc10 strain, which were docked to
octapeptides corresponding to the six authentic cleavage sites (P4–
P4′ sites) of the ORF1 polyprotein of the Mc10 strain (see Materials
and Methods for details; Figure 1). The amino acid sequences of
the six octapeptides are very different from each other (Figure 1A).
Despite the variation, the octapeptides bound to the protease with
the same orientation in the clefts of the protease (Figure 1B);
the P1–P4 amino acid residues bound to the cleft between the
N- and C-terminal domains, whereas the P1′–P4′ amino acid
residues bound to the cleft on the C-terminal domain. The dock-
ing positions were functionally reasonable, because they allowed
the cleavage sites of the octapeptides to be placed near the amino
acids essential for the catalytic activity of the SaV protease, i.e.,
H31, E52, C116, and H131 (Oka et al., 2005b). Other docking posi-
tions caused docking results with very poor docking scores and did
not fulfill the functional requirement for the catalytic reaction.
The protease-peptide complex models disclosed two interac-
tion sites that were common to the six bound peptides. First, the
substrate amino acid residues at the P4 position were exclusively
placed in a thin cleft, termed cleft 1, that was formed by threo-
nine (T), glutamic acid (E), and tyrosine (Y) at positions 30, 52,
and 101 of the protease domain (T30, E52, and Y101, respectively;
Figures 2A–C). An aromatic ring of the phenylalanine (F) or Y
at P4 of the octapeptides of the NS1/NS2, NS2/NS3, NS3/NS4,
NS5/NS6-7, and NS6-7/VP1 cleavage sites (Figure 1A) was posi-
tioned such that an aromatic stacking could be generated with the
Y101 in the protease cleft 1 (Figures 2A–C). The steric configura-
tion of the aromatic rings of the P4 amino acid residues in the
bound state was very similar except for the Y of the NS5/NS6-7
cleavage site (Figure 2C). In the case of the NS4/NS5 peptide, the
P4 amino acid is the arginine (R; Figure 1A) and was arranged
near the side chain of the E52 (Figure 2C).
Second, the substrate amino acid residues at the P1 site were
exclusively placed in a small positively charged cleft, termed cleft
2, that was formed by the histidine (H), H, lysine (K), and R at
positions 14, 31, 112, and 113 of the protease domain (H14, H31,
K112, and R113, respectively; Figures 2D–F). In four out of the
six cleavage sequences the P1 amino acid is negatively charged (E;
Figure 1A) that could interact electrostatically with the side chains
of the positively charged cleft 2 of the protease (Figure 2D). In the
case of the NS2/NS3 and NS3/NS4, the P1 amino acid was glut-
amine (Q; Figure 1A) which is hydrophilic and thus could cause
electrostatic interactions via a polarized charge. The steric configu-
ration of the side chains of the P1 amino acid residues at the bound
state was very similar (Figure 2F). The simulated docking between
the protease and the substrate having alanine substitutions at P1
and P4 positions resulted in a docking position similar to that for
the wild-type substrate, whereas the docking score was reduced to
about 1/2. Collectively, these results suggest that the interactions at
the P1 and P4 sites of the substrates play a key role in the substrate
recognition, as suggested in the previous experiments (Robel et al.,
2008; Oka et al., 2009).
FIGURE 1 | Structural models of SaV protease docked to the substrate
octapeptides. (A) Sequences of the six cleavage sites of the SaV ORF1
polyprotein are shown with one-letter amino acid codes. Slashes represent
the peptide bonds cleaved by the protease. (B) Structural models of the
SaV protease-substrate complex. The 3-D structural model of the protease
domain was constructed by homology modeling and thermodynamically
and physically refined as described previously (Oka et al., 2007). The 3-D
structural models of the octapeptides corresponding to the six authentic
cleavage sites of the SaV Mc10 ORF1 were constructed by using the
Molecular Builder tool in MOE. The optimized protease model was docked
to individual octapeptides using the automated ligand docking program
ASEDock2005 (Goto et al., 2008) operated in MOE as described previously
(Yokoyama et al., 2010). Red and orange sticks indicate main and side chains
of the octapeptides, respectively.
AMINO ACID DIVERSITY OF HUMAN SaV PROTEASE
To obtain evolutionary insights into the protease-substrate inter-
actions, we analyzed the amino acid diversity of the protease
domain among various human SaV strains in the public data-
base. Full-length human SaV protease domain sequences were
collected from GenBank (N = 19) and used to calculate the Shan-
non entropy scores, H (Shannon, 1948), in order to analyze the
diversity of individual amino acid residues in the SaV population
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FIGURE 2 | Close-up views of the interaction sites in the
protease-substrate complex models.The sites of interactions between
the SaV Mc10 protease and the side chains of octapeptides at the P4 (A–C)
and P1 (D–F) sites are highlighted. Upper panels show the cleft formed by
T30, E52, and Y101, and the positively charged cleft formed by the H14, H31,
K112, and R113 of the proteases that are bound to a side chain of the
NS6-7/VP1 octapeptide at the P4 (A) and P1 (D) sites. Middle panels show
the relative configurations of side chains of the protease bound to a side
chain of the NS6-7/VP1 octapeptide at the P4 (B) and P1 (E) sites. Bottom
panels show the superposed structures of the side chains of the P4 (C) and
P1 (F) amino acid residues of the 6 cleavage sites in the SaV
protease-substrate complex models. (C) Green, magenta, and blue sticks
represent the side chains of phenylalanine, tyrosine, and arginine,
respectively, at the P4 site in the substrate-protease complexes. (F) Red
and magenta sticks represent the side chains of glutamic acid and
glutamine, respectively, at the P1 site in the substrate-protease complexes.
as described previously (Oka et al., 2009). The H scores generally
ranged from 0.0 to 0.6 bits (Figure 3A), indicating that the diver-
sity of the SaV protease is relatively small, as seen in many viral
enzymes. The variable sites were essentially located on the surface
region, indicating that some exposed regions of the SaV protease
allow amino acid changes (Figure 3A, greenish sites). Although less
extensive, some variation was detected at Y101 and R113 in the clefts
1 and 2, respectively (Figure 3A, two dotted circles). However,
when the H scores were calculated on the basis of chemical prop-
erties or the size of the amino acid residues, they were nearly zero
throughout the substrate-binding cleft (Figures 3B,C). Similarly,
the protease amino acid residues, which constitute a large cav-
ity for the binding of entire octapeptides, were sometime variable
but highly conserved in the context of the chemical properties
FIGURE 3 | Diversity of SaV protease amino acid residues.The amino
acid diversity at individual sites of the SaV protease domain was analyzed
with information entropy as described previously (Oka et al., 2009). The
Shannon entropy H was calculated with Shannon’s formula (Shannon, 1948)
based on amino acid residues (A), chemical properties (B), and the size of
the side chain (C) using amino acid sequences of the SaV full-length
protease domain from GenBank (N =19). For analysis of the diversity in the
chemical properties, the amino acid residues were classified into seven
groups: acidic (D,E), basic (R,K,H), neutral hydrophilic (S, T, N, Q), aliphatic
(G, A, V, I, L, M), aromatic (F, Y, W), thio-containing (C), and imine (P). For
analysis of the diversity in the size of the side chain, the amino acid
residues were classified into 4 groups: small (G, A, C, S), medium-small (T,
V, N, D, I, L, P, M), medium-large (Q, E, R, K), and large (H, F, Y, W). The H
scores are plotted on the 3-D structure of the SaV protease model, where
an H score of zero indicates absolute conservation. Yellow and orange
dotted circles indicate clefts 1 and 2, respectively.
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and sizes of the side chains (Figures 1B and 3). Thus the
SaV protease appears to restrict extensive changes in the shape
and chemical properties of the substrate-binding surface for its
survival.
SITE-DIRECTED MUTAGENESIS OF SaV PROTEASE
Consistent with the above structural and diversity data, we pre-
viously reported that the E52 in cleft 1, as well as H14 and H31
in cleft 2, are essential to maintain proper processing by SaV
protease (Oka et al., 2007). To obtain further insights into the
biological roles of clefts 1 and 2 in the proteolysis of the SaV pre-
cursor polyprotein, we performed additional site-directed muta-
genesis using a full-length clone of SaV Mc10 strain (Oka et al.,
2005b). The Mc10 ORF1 encodes a polypeptide of 2278 amino
acid residues, where the six cleavage sites have been experimen-
tally determined (Oka et al., 2006; Figure 4A). A total of nine
mutants of the SaV protease domain were constructed using the
Mc10 ORF1. Full-length ORF1 precursor proteins having a sin-
gle or double mutations in the protease domain were expressed
using the in vitro transcription-translation system, and the pro-
cessing products were analyzed by gel electrophoresis as described
previously (Oka et al., 2005b, 2006, 2007, 2009). The Mc10 func-
tional protease (Prowt) and a defective mutant completely lacking
the proteolysis activity (Promut; Oka et al., 2005b) were used as
positive and negative controls of the proteolysis, respectively.
When the ORF1 containing the Prowt was expressed, nine prod-
ucts corresponded in size to the mature proteins NS1, NS2, NS3,
NS4, NS5, and VP1, and relatively stable intermediate proteins,
FIGURE 4 | Site-directed mutagenesis of the substrate interaction sites
of SaV Mc10 protease. (A) Proteolytic cleavage map of the SaV Mc10 ORF1
polyprotein and the processing intermediates (Oka et al., 2006). Black bars
indicate the protein segments, A and D, used to raise polyclonal antibodies for
detection of the NS1 and NS5 proteins, respectively. (B) SDS-PAGE of
35S-labeled in vitro translation products of SaV Mc10 ORF1 containing various
protease mutants. NS1 and NS5 were detected by immunoprecipitation using
anti-A or anti-D polyclonal antibodies as described previously (Oka et al.,
2005b, 2006, 2009). Mc10 ORF1 containing functional protease (Prowt) and a
defective mutant lacking in the proteolysis activity (Promut) were included as
described previously (Oka et al., 2005b). Newly appearing products when
compared to Prowt are indicated by asterisks. Size markers are shown on the
left. Mc10 ORF1-specific proteins (Oka et al., 2005b, 2006) are shown on the
right.
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such as NS2-3, NS4-5, and NS4-5-6-7 were detected (Figure 4B,
lane Prowt, black arrowheads; Oka et al., 2005b, 2006, 2009).
These products were undetectable in the Promut ORF1 sample,
and instead a product corresponding to the ORF1 polyprotein
was detected (Figure 4B, lane Promut, open triangle; Oka et al.,
2005b, 2006, 2009). A single alanine substitution at T30 in the cleft
1, K112 in the cleft 2, or R113 in the cleft 2 of viral protease resulted
in a processing pattern similar to that of Prowt (Figure 4B, lanes
T30A, K112A, and R113A). On the other hand, a single alanine
substitution at Y101 in the cleft 1 (Y101A), a single acidic substitu-
tion at K112 or R113 in the cleft 2 (K112E and R113E), and double
mutations in each cleft (T30AY101A and K112ER113E) resulted
in abnormality of the precursor processing, i.e., an increase in
accumulation of the full-length ORF1 polyprotein and/or the
NS4-5-6-7-VP1 intermediate protein (Figure 4B, asterisks). In
the samples expressing ORF1 with T30A/Y101A or K112E/R113E
double mutations, processing products corresponding to the NS5
and NS4-5 disappeared almost completely (Figure 4B, lanes 5 and
11, respectively).
PHARMACOPHORE-BASED IN SILICO SCREENING FOR THE LEAD
COMPOUNDS OF SaV PROTEASE INHIBITORS
To further assess the role of the clefts 1 and 2 in the ligand bind-
ing, we performed a pharmacophore-based in silico screening
of protease inhibitors. A total of 139,369 compounds (molecu-
lar weights 42–2986) were screened for the lead molecules that
contain an aromatic-ring-like portion resembling the P4 amino
acid, a negatively charged portion resembling the P1 amino acid,
and a hydrophobic portion resembling the P1′ amino acid, being
arranged at similar 3-D positions with the authentic substrates
(Figure 5). The hydrophobic portion resembling the P1′ amino
acid was included to better mimic the authentic substrate struc-
tures. A total of 151 lead compounds matched to the category
were then subjected to the in vitro trans cleavage assay of the SaV
Mc10 ORF1 polyprotein. With this screening, we could obtain
three compounds that inhibited processing of the SaV ORF1 at
IC50 values of 18.4–26.5µM (Figure 6).
We then analyzed how the lead compounds bound to the SaV
Mc10 protease by docking simulation (Figure 7). As expected,
these compounds were predicted to bind to the protease at the
same interaction sites by which the authentic substrates bound
to the protease. The aromatic-ring-like portion resembling the P4
amino acid bound to the thin cleft formed by T30, E52, and Y101 for
the binding of the side chain of the P4 amino acid. The negatively
charged portion resembling the P1 amino acid bound to the small
positively charged pocket formed by the H14, H31, K112, and R113
for the binding of the side chain of the P1 amino acid.
DISCUSSION
The viral proteins that support viral replication and make up the
viral particle are often translated as part of polyprotein precursors.
Viral protease catalyzes cleavage of the precursor protein and thus
plays an essential role in the viral life cycle. In this study, by com-
bining computational and experimental approaches, we studied
the structural basis for the substrate recognition by SaV protease.
The results obtained in this study were consistent with each other
FIGURE 5 | Flow chart for screening chemical compounds against SaV
protease. Pharmacophore-based in silico screening (Schuster et al., 2006a,b;
Kirchmair et al., 2007) was applied to extract the lead compounds having
structural features that resembled those of the substrates of SaV protease.
One hundred and fifty-one compounds exhibiting some similarities to the
authentic substrates were further assessed with respect to their inhibitory
activity against SaV protease. With this strategy, we could obtain three
compounds that inhibited the processing of the SaV ORF1 polyprotein.
and disclosed novel structural base points of the protease for the
attractive interactions with specific structures of ligands.
Using a homology modeling and a docking tool, we first
examined the physical interactions of SaV protease and octapep-
tides corresponding to the six authentic cleavage sites of the SaV
ORF1 polyprotein. Despite the marked sequence variation of the
octapeptides, they were bound to the protease in the same orien-
tation in the structural models (Figure 1). The results suggested
that there might be common interaction sites that served as ful-
crums to direct the orientation of the octapeptides. Consistently,
the models disclosed two interaction sites that were shared with the
six peptides and support the stable and functional binding of sub-
strates to the catalytic cavity; the variable side chains at the P4 and
P1 sites of the peptides were consistently bound to the two small
clefts, termed clefts 1 and 2, respectively (Figure 2). The former
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FIGURE 6 | Dose-response curves of the inhibitors against SaV
protease.The inhibitory effects of the three chemical compounds that were
screened for their structural similarity to the authentic substrates of SaV
protease were determined with an in vitro trans cleavage assay. A
radiolabeled full-length Mc10 ORF1 polyprotein containing a defective
protease (Promut; Oka et al., 2005b) or a non-radiolabeled partial Mc10 ORF1
polyprotein (NS6-7-VP1) containing a functional protease (Prowt; Oka et al.,
2006) was separately expressed using the in vitro transcription/translation
system. The translation products were mixed and incubated in the presence
of increasing concentrations of the indicated compounds at 30˚C for 20 h.
The intensity of the radioactive band corresponding to the NS4-NS5 product
was measured with Typhoon 7500 and plotted in relation to the compound
concentrations. (A) Compound No.50. (B) Compound No.100. (C)
Compound No.116.
participated in aromatic stacking interactions, whereas the latter
participated in electrostatic interactions. These results are consis-
tent with the previous findings that the P4 and P1 amino acid
residues of the substrates play key roles in efficient proteolysis by
SaV protease (Robel et al., 2008; Oka et al., 2009) and predicted that
these two clefts could play a key role in substrate recognition via
interactions with the P4 and P1 amino acid residues of substrates.
This prediction was assessed by several analyses. If the clefts
played essential roles in recognition of substrates, spontaneous
mutations that alter profoundly the physicochemical properties of
the clefts should be suppressed for viral survival. Consistently our
Shannon entropy study using protease sequences of various SaV
FIGURE 7 | Structural models of SaV protease docked to the inhibitors.
Molecular formulas of the inhibitors (left) and structural models of the
inhibitor-protease complexes (right) are shown. Molecular models of the
three chemical compounds having anti-SaV-protease activity were
constructed using the Molecular Builder tool in MOE. Individual compounds
were docked to the SaV protease domain model using the automated
ligand docking program ASEDock2005 (Goto et al., 2008). Light blue sticks
in the protease indicate inhibitors. Greenish and bluish portions of the
protease indicate an aromatic and hydrophobic site and positively charged
site, respectively. (A) Compound No.50. (B) Compound No.100. (C)
Compound No.116.
strains from the world shows that the amino acid residues forming
the clefts 1 and 2 are variable but highly conserved in terms of the
chemical properties or the sizes of side chains (Figure 3). The
results indicate that these clefts tolerate mutations in nature but
resist a range of mutations that markedly alter the chemical prop-
erties or the shapes of the cleft surface. The findings are consistent
with the above structure-based prediction on the function of the
clefts 1 and 2. These clefts are located on the surface of the large
cavity of the protease. Therefore, the restrictions in the variation
in two clefts are likely to be caused by functional constraints for
the essential interactions.
Moreover, we examined whether a range of mutations that
markedly alter the physicochemical properties of the clefts indeed
could result in aberrant processing of the SaV precursor polypro-
tein. Our site-directed mutagenesis study showed that a single
mutation in cleft 1 (T30A) or in cleft 2 (K112A or R113A) caused
little detectable damage in the processing of the viral precursor
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polyprotein, showing a tolerance to mutations as indicated by our
information entropy study. Notably, however, (i) a single mutation
that causes a loss of aromatic stacking interaction (Y101A) in the
cleft 1, (ii) a single mutation that causes a loss of the electrosta-
tic interaction in the cleft 2 (K112E or R113E), and (iii) double
mutations within the clefts unexceptionally resulted in incomplete
processing (Figure 4). The results indicate that the abnormal pro-
cessing was caused only by single mutations that could extensively
alter the chemical properties of the clefts. The data agree with the
entropy data and again suggest the acceptability of variation in the
two clefts under functional constraints.
Finally, we performed in silico screening of SaV protease
inhibitors on the basis of the above structural and biological infor-
mation. The screening of the 139,369 compounds in silico led to
the identification of the 151 compounds that resembled the struc-
tural and spatial features of the P4 and P1 amino acid residues
of authentic substrates (Figure 5). From them, we could experi-
mentally identify the three compounds that inhibited proteolysis
of the SaV precursor polyprotein in vitro (Figure 6). As expected,
these compounds were predicted to bind to the SaV protease at
the two clefts via similar attractive interactions with the authentic
ligands (Figure 7). These results provide additional evidence that
two clefts on the SaV protease cavity play a key role in the ligand
recognition by providing the structural base points for the specific
attractive interactions.
Notably, six cleavage sites of SaV precursor polyprotein also
differ with respect to their susceptibility to the SaV protease, with
the NS2/NS3, NS4/NS5, and NS5/NS6-7 sites being consistently
more resistant to the cleavage than the NS1/NS2, NS3/NS4, and
NS6-7/VP1 sites (Oka et al., 2005b, 2006, 2009). In this regard,
it is of note that the P4 position of the NS4/NS5 site of human
SaV is exclusively arginine instead of an aromatic amino acid
(Figure 1A) and that this arginine is conserved in all human
SaV strains reported thus far (Oka et al., 2005b, 2006, 2009). This
substitution at P4 position will abolish the aromatic stacking inter-
action in the cleft 1 and thus will attenuate attractive interactions
between protease and the NS4/NS5 cleavage site. This possibility
is well consistent with the experimental findings; the cleavage of
the NS4/NS5 site is less efficient than that of the other sites (Oka
et al., 2005b, 2006, 2009) and is more sensitive to the cleft 1 muta-
tions than the other cleavage sites are (Figure 4, lane 5, NS5).
Moreover, the attenuation of cleavage of the NS4/NS5 site was
reversed simply by replacing the arginine with phenylalanine at
the P4 site (Oka et al., 2009). These findings strongly suggest that
the well-preserved arginine at the P4 position of the SaV NS4/NS5
cleavage site plays a key role in maintaining the distinct cleavability
of precursor polyprotein by SaV protease.
In this study, we disclosed a novel 3-D pharmacophore con-
taining two clefts on the cavity of the SaV protease, which can be
used to identify the lead compounds of SaV protease inhibitors.
SaV is one of the commonly detected pathogens in the acute gas-
troenteritis of both children and adults (Johansson et al., 2005;
Harada et al., 2009; Iturriza-Gomara et al., 2009; Pang et al., 2009).
Diarrhea is one of the greatest causes of mortality in children
under age 5 in many countries (Boschi-Pinto et al., 2008), and
the outbreaks of the acute gastroenteritis often seriously affects
the clinical, economic, and social activities. Therefore, anti-viral
compounds against SaV may be beneficial to some at-risk pop-
ulations or communities. Thus far no anti-SaV inhibitors for
the clinical use have been developed. Our findings will provide
important clues to the unique specificity of the SaV protease, the
regulation of SaV maturation, and the rationale design of anti-SaV
inhibitors.
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